85 related articles for article (PubMed ID: 12581510)
1. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
Asking L; Lundbäck H; Persson B
J Aerosol Med; 2002; 15(4):435-6; author reply 436-8. PubMed ID: 12581510
[No Abstract] [Full Text] [Related]
2. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
Chew NY; Chan HK
J Aerosol Med; 2001; 14(4):495-501. PubMed ID: 11791690
[TBL] [Abstract][Full Text] [Related]
3. Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler.
Lötvall J; Mellén A; Arvidsson P; Palmqvist M; Radielovic P; Kottakis J; Pfister P
Can Respir J; 1999; 6(5):412-6. PubMed ID: 10572207
[TBL] [Abstract][Full Text] [Related]
4. Single-dose comparison of formoterol (Oxis) Turbuhaler 6 microg and formoterol Aerolizer 12 microg in moderate to severe asthma: a randomised, crossover study.
Schlimmer P
Pulm Pharmacol Ther; 2002; 15(4):369-74. PubMed ID: 12220942
[TBL] [Abstract][Full Text] [Related]
5. In vitro testing of two formoterol dry powder inhalers at different flow rates.
Weuthen T; Roeder S; Brand P; Müllinger B; Scheuch G
J Aerosol Med; 2002; 15(3):297-303. PubMed ID: 12396417
[TBL] [Abstract][Full Text] [Related]
6. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.
Eliraz A; Ramirez-Rivera A; Ferranti P; Holzer R; García JM; Turcotte C; Rapatz G; Pfister P; Overend T; Kottakis J
Int J Clin Pract; 2001 Apr; 55(3):164-70. PubMed ID: 11351769
[TBL] [Abstract][Full Text] [Related]
7. Aerosol tribocharging and its relation to the deposition of Oxis™ Turbuhaler® in the electrical next generation impactor.
Hoe S; Young PM; Traini D
J Pharm Sci; 2011 Dec; 100(12):5270-80. PubMed ID: 21850666
[TBL] [Abstract][Full Text] [Related]
8. Hollow porous particles in metered dose inhalers.
Dellamary LA; Tarara TE; Smith DJ; Woelk CH; Adractas A; Costello ML; Gill H; Weers JG
Pharm Res; 2000 Feb; 17(2):168-74. PubMed ID: 10751031
[TBL] [Abstract][Full Text] [Related]
9. Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).
Zhou QT; Tong Z; Tang P; Citterio M; Yang R; Chan HK
AAPS J; 2013 Apr; 15(2):511-22. PubMed ID: 23371759
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers.
Petzold U; Kremer HJ; Nguyen DT; Munzel U; Dietrich H; Maus J
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):309-19. PubMed ID: 18598160
[TBL] [Abstract][Full Text] [Related]
11. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single-dose capsule inhaler.
Criée CP; Meyer T; Petro W; Sommerer K; Zeising P
J Aerosol Med; 2006; 19(4):466-72. PubMed ID: 17196075
[TBL] [Abstract][Full Text] [Related]
12. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
[TBL] [Abstract][Full Text] [Related]
13. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data.
Meyer T; Brand P; Ehlich H; Köbrich R; Meyer G; Riedinger F; Sommerer K; Weuthen T; Scheuch G
J Aerosol Med; 2004; 17(1):43-9. PubMed ID: 15120012
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of formoterol (Oxis) turbuhaler plus budesonide (Pulmicort) turbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia.
Chuchalin AG; Ovcharenko SI; Goriachkina LA; Sidorenko IV; Tsoi AN;
Int J Clin Pract; 2002; 56(1):15-20. PubMed ID: 11833550
[TBL] [Abstract][Full Text] [Related]
16. Delivery of formoterol from a novel multi-dose inhaler Airmax.
Zeng XM; Jones S; O'Leary D; Phelan M; Colledge J
Respir Med; 2002 Jun; 96(6):397-403. PubMed ID: 12117038
[TBL] [Abstract][Full Text] [Related]
17. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
Brusasco V; Canonica GW; Dal Negro R; Scano G; Paggiaro P; Fabbri LM; Barisione G; D'Amato G; Varoli G; Baroffio M; Milanese M; Mereu C; Crimi E
J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
[TBL] [Abstract][Full Text] [Related]
18. Dose dependency between the effect (FEV1) and the administered dose.
Dubois EF
Respir Med; 2003 Jul; 97(7):859. PubMed ID: 12854638
[No Abstract] [Full Text] [Related]
19. Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting.
Lee-Wong M; Chou V; Ogawa Y
Ann Allergy Asthma Immunol; 2008 Feb; 100(2):146-52. PubMed ID: 18320916
[TBL] [Abstract][Full Text] [Related]
20. Particle-size distribution of bitolterol mesylate solution delivered by four compressed-air nebulizer devices.
Hunke WA; Yu AB
Am J Hosp Pharm; 1987 Jun; 44(6):1392-6. PubMed ID: 3618619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
